Market Cap 800.22M
Revenue (ttm) 0.00
Net Income (ttm) -106.19M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 961,600
Avg Vol 676,750
Day's Range N/A - N/A
Shares Out 103.39M
Stochastic %K 99%
Beta 0.40
Analysts Strong Sell
Price Target $19.00

Company Profile

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 500 8864
Address:
80 Guest Street, 5th Floor, Boston, United States
topstockalerts
topstockalerts Jul. 3 at 8:08 PM
$AURA the chart looks very constructive right here
0 · Reply
STACKD0E
STACKD0E Jul. 2 at 8:20 PM
0 · Reply
SevenPhigs27
SevenPhigs27 Jul. 1 at 7:03 PM
$AURA Added. The selling volume is minimal. I guess we'll see.
0 · Reply
PLUS20LEVERAGE
PLUS20LEVERAGE Jul. 1 at 5:04 PM
0 · Reply
PLUS20LEVERAGE
PLUS20LEVERAGE Jul. 1 at 4:46 PM
0 · Reply
SevenPhigs27
SevenPhigs27 Jul. 1 at 4:42 PM
$AURA Took a starter. GLTA
0 · Reply
Dcvfin
Dcvfin Jun. 10 at 1:23 AM
$AURA starting to look yummy
0 · Reply
DARKP00L
DARKP00L Jun. 1 at 1:59 PM
$AURA 08:14 on Jun. 01 2026 Aura Biosciences Announces 108 Patients Enrolled In The Phase 3 Trial Evaluating Belzupacap Sarotalocan As A Frontline Treatment For Patients With Early Choroidal Melanoma; Topline Data Expected In H2 2027 #tradeideas
0 · Reply
MarketBeat
MarketBeat May. 27 at 8:06 PM
https://marketbeat.com/a/8678516/ $AURA Aura Biosciences Gears Up for Bel-Sar Filing as Pivotal Eye Cancer Trial Advances
0 · Reply
MarketBeat
MarketBeat May. 20 at 2:04 AM
https://marketbeat.com/a/8663626/ $AURA Aura Biosciences Highlights Bel-Sar Eye Cancer Strategy, Mid-Year Bladder Data
0 · Reply
Latest News on AURA
Aura Biosciences Proxy statement: Proxy filing

Jun 29, 2026, 8:00 AM EDT - 5 days ago

Aura Biosciences Proxy statement: Proxy filing


Aura Biosciences Proxy statement: Proxy filing

Jun 17, 2026, 8:00 AM EDT - 17 days ago

Aura Biosciences Proxy statement: Proxy filing


Aura Biosciences Transcript: AGM 2026

Jun 11, 2026, 9:30 AM EDT - 23 days ago

Aura Biosciences Transcript: AGM 2026


Aura Biosciences Earnings release: Q1 2026

May 11, 2026, 4:00 PM EDT - 7 weeks ago

Aura Biosciences Earnings release: Q1 2026


Aura Biosciences Quarterly report: Q1 2026

May 11, 2026, 4:00 PM EDT - 7 weeks ago

Aura Biosciences Quarterly report: Q1 2026


Aura Biosciences Slides: Corporate presentation

May 11, 2026, 4:00 PM EDT - 7 weeks ago

Aura Biosciences Slides: Corporate presentation


Aura Biosciences Slides: Corporate presentation

May 5, 2026, 7:00 AM EDT - 2 months ago

Aura Biosciences Slides: Corporate presentation


Aura Biosciences $260M Spot Secondary priced at $6.00

2026-05-04T13:38:00.000Z - 2 months ago

Aura Biosciences $260M Spot Secondary priced at $6.00


Aura Biosciences Proxy statement: Proxy filing

May 4, 2026, 8:00 AM EDT - 2 months ago

Aura Biosciences Proxy statement: Proxy filing


Aura Biosciences Proxy statement: Proxy filing

Apr 20, 2026, 8:00 AM EDT - 2 months ago

Aura Biosciences Proxy statement: Proxy filing


Aura Biosciences Proxy statement: Proxy filing

Apr 20, 2026, 8:00 AM EDT - 2 months ago

Aura Biosciences Proxy statement: Proxy filing


Aura Biosciences Annual report: Q4 2025

Mar 30, 2026, 7:00 AM EDT - 3 months ago

Aura Biosciences Annual report: Q4 2025


Aura Biosciences Earnings release: Q4 2025

Mar 30, 2026, 7:00 AM EDT - 3 months ago

Aura Biosciences Earnings release: Q4 2025


Aura Biosciences Slides: Corporate presentation

Mar 27, 2026, 8:00 AM EDT - 3 months ago

Aura Biosciences Slides: Corporate presentation


Aura Biosciences reports Q3 EPS (40c), consensus (47c)

2025-11-13T12:10:46.000Z - 8 months ago

Aura Biosciences reports Q3 EPS (40c), consensus (47c)


Aura Biosciences Earnings release: Q3 2025

Nov 13, 2025, 7:00 AM EST - 8 months ago

Aura Biosciences Earnings release: Q3 2025


Aura Biosciences Quarterly report: Q3 2025

Nov 13, 2025, 7:00 AM EST - 8 months ago

Aura Biosciences Quarterly report: Q3 2025


Aura Biosciences reports Q2 EPS (47c) vs (41c) last year

2025-08-13T11:10:59.000Z - 11 months ago

Aura Biosciences reports Q2 EPS (47c) vs (41c) last year


Aura Biosciences Quarterly report: Q2 2025

Aug 13, 2025, 7:00 AM EDT - 11 months ago

Aura Biosciences Quarterly report: Q2 2025


Aura Biosciences Earnings release: Q2 2025

Aug 13, 2025, 7:00 AM EDT - 11 months ago

Aura Biosciences Earnings release: Q2 2025


Aura Biosciences assumed with a Buy at H.C. Wainwright

2025-05-28T10:10:24.000Z - 1 year ago

Aura Biosciences assumed with a Buy at H.C. Wainwright


Aura Biosciences Slides: Corporate Presentation

May 16, 2025, 7:00 AM EDT - 1 year ago

Aura Biosciences Slides: Corporate Presentation


Aura Biosciences 11.7M share Spot Secondary priced at $4.90

2025-05-15T13:35:36.000Z - 1 year ago

Aura Biosciences 11.7M share Spot Secondary priced at $4.90


Aura Biosciences Quarterly report: Q1 2025

May 15, 2025, 6:00 AM EDT - 1 year ago

Aura Biosciences Quarterly report: Q1 2025


Aura Biosciences Earnings release: Q1 2025

May 15, 2025, 6:00 AM EDT - 1 year ago

Aura Biosciences Earnings release: Q1 2025


Aura Biosciences Proxy statement: Proxy Filing

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Aura Biosciences Proxy statement: Proxy Filing


Aura Biosciences Proxy statement: Proxy Filing

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Aura Biosciences Proxy statement: Proxy Filing


Aura Biosciences appoints Bitetti to board of directors

2025-04-02T11:15:32.000Z - 1 year ago

Aura Biosciences appoints Bitetti to board of directors


Aura Biosciences Transcript: Status Update

Mar 24, 2025, 4:30 PM EDT - 1 year ago

Aura Biosciences Transcript: Status Update


Aura Biosciences Press release: Status Update

Mar 24, 2025, 4:30 PM EDT - 1 year ago

Aura Biosciences Press release: Status Update


Aura Biosciences Slides: Status Update

Mar 24, 2025, 4:30 PM EDT - 1 year ago

Aura Biosciences Slides: Status Update


Aura Biosciences Annual report: Q4 2024

Mar 24, 2025, 10:30 AM EDT - 1 year ago

Aura Biosciences Annual report: Q4 2024


Aura Biosciences Earnings release: Q4 2024

Mar 24, 2025, 10:30 AM EDT - 1 year ago

Aura Biosciences Earnings release: Q4 2024


Aura Biosciences Earnings release: Q3 2024

Nov 12, 2024, 9:30 AM EST - 1 year ago

Aura Biosciences Earnings release: Q3 2024


Aura Biosciences Quarterly report: Q3 2024

Nov 12, 2024, 9:30 AM EST - 1 year ago

Aura Biosciences Quarterly report: Q3 2024


Aura Biosciences Transcript: Status Update

Oct 17, 2024, 4:30 PM EDT - 1 year ago

Aura Biosciences Transcript: Status Update


Aura Biosciences Press release: Status Update

Oct 17, 2024, 4:30 PM EDT - 1 year ago

Aura Biosciences Press release: Status Update


Aura Biosciences Slides: Status Update

Oct 17, 2024, 4:30 PM EDT - 1 year ago

Aura Biosciences Slides: Status Update


Aura Biosciences Transcript: Status Update

Sep 12, 2024, 8:00 AM EDT - 1 year ago

Aura Biosciences Transcript: Status Update


Aura Biosciences Press release: Status Update

Sep 12, 2024, 8:00 AM EDT - 1 year ago

Aura Biosciences Press release: Status Update


Aura Biosciences Quarterly report: Q2 2024

Aug 8, 2024, 7:15 AM EDT - 2 years ago

Aura Biosciences Quarterly report: Q2 2024


Aura Biosciences Earnings release: Q2 2024

Aug 8, 2024, 7:15 AM EDT - 2 years ago

Aura Biosciences Earnings release: Q2 2024


Aura Biosciences Proxy statement: Proxy Filing

Jun 14, 2024, 8:00 AM EDT - 2 years ago

Aura Biosciences Proxy statement: Proxy Filing


Aura Biosciences Transcript: Status Update

May 29, 2024, 2:00 PM EDT - 2 years ago

Aura Biosciences Transcript: Status Update


Aura Biosciences Quarterly report: Q1 2024

May 9, 2024, 7:00 AM EDT - 2 years ago

Aura Biosciences Quarterly report: Q1 2024


Aura Biosciences Earnings release: Q1 2024

May 9, 2024, 7:00 AM EDT - 2 years ago

Aura Biosciences Earnings release: Q1 2024


Aura Biosciences Proxy statement: Proxy Filing

Apr 25, 2024, 8:00 AM EDT - 2 years ago

Aura Biosciences Proxy statement: Proxy Filing


Aura Biosciences Proxy statement: Proxy Filing

Apr 25, 2024, 8:00 AM EDT - 2 years ago

Aura Biosciences Proxy statement: Proxy Filing


Aura Biosciences Proxy statement: Proxy Filing

Apr 15, 2024, 8:00 AM EDT - 2 years ago

Aura Biosciences Proxy statement: Proxy Filing


Aura Biosciences Registration statement: Registration Filing

Mar 27, 2024, 8:00 AM EDT - 2 years ago

Aura Biosciences Registration statement: Registration Filing


Aura Biosciences Earnings release: Q4 2023

Mar 27, 2024, 7:00 AM EDT - 2 years ago

Aura Biosciences Earnings release: Q4 2023


Aura Biosciences Annual report: Q4 2023

Mar 27, 2024, 7:00 AM EDT - 2 years ago

Aura Biosciences Annual report: Q4 2023


Aura Biosciences Quarterly report: Q3 2023

Nov 9, 2023, 7:00 AM EST - 2 years ago

Aura Biosciences Quarterly report: Q3 2023


Aura Biosciences Earnings release: Q3 2023

Nov 9, 2023, 7:00 AM EST - 2 years ago

Aura Biosciences Earnings release: Q3 2023


Aura Biosciences Slides: Corporate Presentation

Nov 3, 2023, 8:00 AM EDT - 2 years ago

Aura Biosciences Slides: Corporate Presentation


Aura Biosciences Quarterly report: Q2 2023

Aug 9, 2023, 7:00 AM EDT - 3 years ago

Aura Biosciences Quarterly report: Q2 2023


Aura Biosciences Earnings release: Q2 2023

Aug 9, 2023, 7:00 AM EDT - 3 years ago

Aura Biosciences Earnings release: Q2 2023


Aura Biosciences Quarterly report: Q1 2023

May 11, 2023, 7:00 AM EDT - 3 years ago

Aura Biosciences Quarterly report: Q1 2023


Aura Biosciences Earnings release: Q1 2023

May 11, 2023, 7:00 AM EDT - 3 years ago

Aura Biosciences Earnings release: Q1 2023


Aura Biosciences Proxy statement: Proxy Filing

Apr 25, 2023, 8:00 AM EDT - 3 years ago

Aura Biosciences Proxy statement: Proxy Filing


Aura Biosciences Proxy statement: Proxy Filing

Apr 25, 2023, 8:00 AM EDT - 3 years ago

Aura Biosciences Proxy statement: Proxy Filing


Aura Biosciences Annual report: Q4 2022

Mar 15, 2023, 8:00 AM EDT - 3 years ago

Aura Biosciences Annual report: Q4 2022


Aura Biosciences Earnings release: Q4 2022

Mar 15, 2023, 8:00 AM EDT - 3 years ago

Aura Biosciences Earnings release: Q4 2022


Aura Biosciences Slides: Corporate Presentation

Jan 6, 2023, 7:00 AM EST - 3 years ago

Aura Biosciences Slides: Corporate Presentation


Aura Biosciences Registration statement: Registration Filing

Nov 1, 2022, 8:00 AM EDT - 3 years ago

Aura Biosciences Registration statement: Registration Filing


topstockalerts
topstockalerts Jul. 3 at 8:08 PM
$AURA the chart looks very constructive right here
0 · Reply
STACKD0E
STACKD0E Jul. 2 at 8:20 PM
0 · Reply
SevenPhigs27
SevenPhigs27 Jul. 1 at 7:03 PM
$AURA Added. The selling volume is minimal. I guess we'll see.
0 · Reply
PLUS20LEVERAGE
PLUS20LEVERAGE Jul. 1 at 5:04 PM
0 · Reply
PLUS20LEVERAGE
PLUS20LEVERAGE Jul. 1 at 4:46 PM
0 · Reply
SevenPhigs27
SevenPhigs27 Jul. 1 at 4:42 PM
$AURA Took a starter. GLTA
0 · Reply
Dcvfin
Dcvfin Jun. 10 at 1:23 AM
$AURA starting to look yummy
0 · Reply
DARKP00L
DARKP00L Jun. 1 at 1:59 PM
$AURA 08:14 on Jun. 01 2026 Aura Biosciences Announces 108 Patients Enrolled In The Phase 3 Trial Evaluating Belzupacap Sarotalocan As A Frontline Treatment For Patients With Early Choroidal Melanoma; Topline Data Expected In H2 2027 #tradeideas
0 · Reply
MarketBeat
MarketBeat May. 27 at 8:06 PM
https://marketbeat.com/a/8678516/ $AURA Aura Biosciences Gears Up for Bel-Sar Filing as Pivotal Eye Cancer Trial Advances
0 · Reply
MarketBeat
MarketBeat May. 20 at 2:04 AM
https://marketbeat.com/a/8663626/ $AURA Aura Biosciences Highlights Bel-Sar Eye Cancer Strategy, Mid-Year Bladder Data
0 · Reply
billionairehedgeclub
billionairehedgeclub May. 19 at 6:33 PM
$AURA I’m in
0 · Reply
gazza01
gazza01 May. 13 at 12:37 PM
$REPL $AURA doesn't AURA also use modified HPV virus to target melanoma? Hopefully they'll learn from REPL mistakes
3 · Reply
Dcvcool
Dcvcool May. 6 at 12:55 AM
$AURA seems like this finally came up to somewhere close to true value with this experienced CEO taking over Great trial results so far I think this will do well
1 · Reply
Uromaster
Uromaster May. 5 at 2:30 PM
$AURA I am amazed how this stock is riding under the radar. Good movement. Maybe take my winnings and run?
1 · Reply
StockScanners
StockScanners May. 5 at 5:28 AM
$AURA keep watch if this holds above 8
0 · Reply
topstockalerts
topstockalerts May. 4 at 10:47 PM
$AURA this could easily turn into one of those annoying runners you miss 😅
0 · Reply
rando321456
rando321456 May. 4 at 3:19 PM
$AURA That's nearly a ggs here assuming the results of Compass tracks to what the phase 2 showed. We now have both the capital and the enrollment to drive this past the finish line. What's very interesting is that they probably raised about 50-100 million more than they needed to, that tells me they are going to be aggressive with their pipeline and maybe self fund another phase 3. We shall see.
0 · Reply
Shortski
Shortski May. 4 at 1:44 PM
$AURA public offering and this goes up
0 · Reply
DonCorleone77
DonCorleone77 May. 4 at 10:32 AM
$AURA Aura Biosciences announces common stock, pre-funded warrant offering Aura Biosciences announced the launch of an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of common stock. All of the shares of common stock and pre-funded warrants to be sold in the offering will be offered by Aura. Leerink Partners, TD Cowen and Evercore ISI are acting as joint bookrunning managers for the offering. LifeSci Capital is also acting as a bookrunning manager in the offering. Citizens Capital Markets is acting as a co-manager for the offering.
0 · Reply
DARKP00L
DARKP00L Apr. 29 at 11:58 AM
$AURA 07:42 on Apr. 29 2026 HC Wainwright & Co. Maintains Buy on Aura Biosciences, Raises Price Target to $24 #tradeideas
0 · Reply
SuperGreenToday
SuperGreenToday Apr. 23 at 12:41 PM
$AURA Share Price: $7.48 Contract Selected: Oct 16, 2026 $10 Calls Buy Zone: $1.53 – $1.89 Target Zone: $2.49 – $3.04 Potential Upside: 53% ROI Time to Expiration: 175 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
rando321456
rando321456 Apr. 19 at 12:48 PM
$AURA Very tense period of time here imo, the company is putting up quite the poker face not raising into this strength and spending a decent chunk of change cleaning up loose ends with Clearside.
0 · Reply